NO20055150L - Benzotiazolderivater som adenosin-reseptorligander - Google Patents

Benzotiazolderivater som adenosin-reseptorligander

Info

Publication number
NO20055150L
NO20055150L NO20055150A NO20055150A NO20055150L NO 20055150 L NO20055150 L NO 20055150L NO 20055150 A NO20055150 A NO 20055150A NO 20055150 A NO20055150 A NO 20055150A NO 20055150 L NO20055150 L NO 20055150L
Authority
NO
Norway
Prior art keywords
optionally substituted
lower alkyl
aza
halogen
alkyl
Prior art date
Application number
NO20055150A
Other languages
English (en)
Norwegian (no)
Inventor
Roland Jakob-Roetne
Claus Riemer
Alexander Flohr
Roger David Norcross
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20055150L publication Critical patent/NO20055150L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20055150A 2003-05-19 2005-11-03 Benzotiazolderivater som adenosin-reseptorligander NO20055150L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011039 2003-05-19
PCT/EP2004/005178 WO2005000842A1 (fr) 2003-05-19 2004-05-14 Derives de benzothiazole utilises comme ligands de recepteur d'adenosine

Publications (1)

Publication Number Publication Date
NO20055150L true NO20055150L (no) 2005-11-04

Family

ID=33442729

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055150A NO20055150L (no) 2003-05-19 2005-11-03 Benzotiazolderivater som adenosin-reseptorligander

Country Status (27)

Country Link
US (1) US7371748B2 (fr)
EP (1) EP1636223B1 (fr)
JP (1) JP4444290B2 (fr)
KR (1) KR100859886B1 (fr)
CN (1) CN100528871C (fr)
AR (1) AR044362A1 (fr)
AT (1) ATE389652T1 (fr)
AU (1) AU2004251814B2 (fr)
BR (1) BRPI0410440A (fr)
CA (1) CA2524366C (fr)
CL (1) CL2004001067A1 (fr)
CO (1) CO5630031A2 (fr)
DE (1) DE602004012555T2 (fr)
DK (1) DK1636223T3 (fr)
ES (1) ES2301991T3 (fr)
HR (1) HRP20080207T3 (fr)
IL (1) IL171686A (fr)
MX (1) MXPA05012360A (fr)
NO (1) NO20055150L (fr)
NZ (1) NZ543074A (fr)
PL (1) PL1636223T3 (fr)
PT (1) PT1636223E (fr)
RU (1) RU2351597C2 (fr)
SI (1) SI1636223T1 (fr)
TW (1) TW200505882A (fr)
WO (1) WO2005000842A1 (fr)
ZA (1) ZA200509294B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008052930A2 (fr) * 2006-11-03 2008-05-08 F. Hoffmann-La Roche Ag Préparation de dérivés de (tétrahydro-pyran-4-yl)-benzothiazolamine
KR102717280B1 (ko) * 2017-08-01 2024-10-14 메르크 파텐트 게엠베하 아데노신 수용체 길항제로서의 티아졸로피리딘 유도체
TWI791593B (zh) 2017-08-21 2023-02-11 德商馬克專利公司 做為腺苷受體拮抗劑之苯并咪唑衍生物
CN110944994B (zh) * 2017-08-21 2023-06-09 默克专利股份公司 作为腺苷受体拮抗剂的喹喔啉衍生物
WO2019141096A1 (fr) * 2018-01-19 2019-07-25 四川科伦博泰生物医药股份有限公司 Composé d'urée substitué, son procédé de préparation et son utilisation
KR20210083287A (ko) 2018-10-25 2021-07-06 메르크 파텐트 게엠베하 아데노신 수용체 안타고니스트로서의 5-아자인다졸 유도체
CA3117512A1 (fr) 2018-10-25 2020-04-30 Merck Patent Gmbh Derives de 5-azaindazole utilises en tant qu'antagonistes du recepteur de l'adenosine
AR117844A1 (es) * 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI91859C (fi) * 1987-06-17 1994-08-25 Eisai Co Ltd Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
IL90337A0 (en) * 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
CZ2003182A3 (cs) * 2000-06-21 2003-06-18 F. Hoffmann-La Roche Ag Deriváty benzothiazolu
ES2303558T3 (es) * 2001-11-27 2008-08-16 F. Hoffmann-La Roche Ag Derivados de benzotiazol.
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
US6734179B2 (en) * 2001-12-12 2004-05-11 Hoffmann-La Roche Inc. Benzothiazoles
DE602004012388T2 (de) * 2003-01-13 2009-03-12 F. Hoffmann-La Roche Ag Benzoxazolderivate und deren verwendung als adenosinrezeptorliganden

Also Published As

Publication number Publication date
RU2351597C2 (ru) 2009-04-10
AR044362A1 (es) 2005-09-07
JP4444290B2 (ja) 2010-03-31
PT1636223E (pt) 2008-05-06
EP1636223B1 (fr) 2008-03-19
BRPI0410440A (pt) 2006-06-06
HRP20080207T3 (en) 2008-06-30
US7371748B2 (en) 2008-05-13
CO5630031A2 (es) 2006-04-28
CN1791600A (zh) 2006-06-21
CL2004001067A1 (es) 2005-04-15
MXPA05012360A (es) 2006-02-02
CA2524366C (fr) 2012-03-13
KR100859886B1 (ko) 2008-09-23
PL1636223T3 (pl) 2008-07-31
DK1636223T3 (da) 2008-06-23
DE602004012555D1 (de) 2008-04-30
ATE389652T1 (de) 2008-04-15
TW200505882A (en) 2005-02-16
AU2004251814B2 (en) 2009-07-23
ZA200509294B (en) 2006-10-25
HK1092469A1 (zh) 2007-02-09
WO2005000842A1 (fr) 2005-01-06
EP1636223A1 (fr) 2006-03-22
AU2004251814A1 (en) 2005-01-06
KR20060013406A (ko) 2006-02-09
NZ543074A (en) 2009-01-31
CN100528871C (zh) 2009-08-19
JP2006528220A (ja) 2006-12-14
IL171686A (en) 2011-11-30
CA2524366A1 (fr) 2005-01-06
SI1636223T1 (sl) 2008-06-30
ES2301991T3 (es) 2008-07-01
US20040235915A1 (en) 2004-11-25
RU2005139527A (ru) 2006-07-27
DE602004012555T2 (de) 2009-04-16

Similar Documents

Publication Publication Date Title
ES2584055T3 (es) Compuestos heterocíclicos de benzodioxol o benzodioxepina como inhibidores de la fosfodiesterasa
MY140039A (en) Pyrido-(2,1-a)-isoquinoline derivatives as dpp-iv inhibitors
AR040806A1 (es) Derivados de piperidi-2-ona 1,6 disustituidos, composicion farmaceutica que la comprende y metodo de tratamiento
CY1109558T1 (el) Παραγωγα βενζο[d]αζεπινης για την θεραπεια νευρολογικων διαταραχων
DK0944617T3 (da) Krystaller af benzimidazolderivater og deres fremstilling
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
AR037731A1 (es) Uso de ureas de benzotiazoles
DE68908040D1 (de) 3-(4-piperidin)-5-(2-sulphonylaminoethyl)-indol-derivate.
NO20083917L (no) Malonamidderivater som gammasekretaseinhibitorer
DE69013607D1 (de) Pyrazol-Derivate, Verfahren zu deren Herstellung und Anwendung.
NO20080871L (no) N-(Heteroaryl)-1-heteroarylalkyl-1 H-indol-2-karboksamidderivater, fremstilling og terapeutisk anvendelse derav
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
NO20055150L (no) Benzotiazolderivater som adenosin-reseptorligander
NO177138C (no) Analogifremgangsmåte ved fremstilling av substituerte imidazolderivater
BR0010134A (pt) Uso de derivados de ácido 2,4-diamino-3-hidroxicarboxìlico como inibidores de proteassoma
PT76123A (fr) Procede de preparation de nouveaux derives de benzadioxine
NO20052360L (no) Forbedrede formuleringer inneholdende substituerte imidazolderivater
ATE8996T1 (de) Benzo(4,5)pyrano(2,3-c)pyrrole, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
NO20054794L (no) 7 ([1, 4] dioksan-2-yl)-benzotiazolderivater som adenosinreseptorligander
MY140692A (en) Benzothiazole derivatives
NO20065323L (no) 6-substituerte pyridoindolonderivater, fremstilling og anvendelse derav
ATE169300T1 (de) 1'-aminospiro-(isochinolin-4(1h),3'-pyrrolidin> 1,2',3,5'-(2h)-tetrone und analoge verbindungen als inhibitoren der aldose reduktase in vivo
MX2009000798A (es) Inhibidor de nf-kappa b.
NO165593C (no) Analogifremgangsmaate ved fremstilling av nye tetracykliske indolderivater.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application